Hunan Hongya Gene Technology Co., Ltd.

Hunan Hongya Gene Technology Co., Ltd. was initiated and established by clinical pharmacologist, pioneer and founder of genetic pharmacology and pharmacogenomics in China, advocate of individualized medicine, Academician Zhou Honghao and his team. It is a high-tech company dedicated to the research and industrialization development of individualized medicine (precision medicine) testing technology. The company is mainly engaged in the development, operation and market promotion of individualized medicine testing products (including instruments and equipment, reagents and consumables, and testing services), building a professional individualized medicine testing operation service platform in the era of precision medicine. The company collaborates with multiple domestic and international professional research institutions in individualized medicine (precision medicine) represented by the Xiangya Medical Laboratory, introduces an expert technical team represented by national "****" scholar and Medical Director of Moffitt Cancer Center in the United States Howard L. McLeod, integrates advanced domestic and international individualized medicine testing technology platforms, drives production and sales through research and development, and relies on advanced core molecular diagnostic technologies to form a series of products with independent intellectual property rights in the field of in vitro diagnostics, especially high-end molecular diagnostics. The company's current main business includes various molecular testing products used for non-invasive prenatal screening, disease prediction, early disease screening, early molecular diagnosis and molecular typing of diseases, individualized drug guidance for diseases, and disease prognosis monitoring. It has formed a nationwide marketing network and become a leading brand enterprise in the field of professional individualized medicine (precision medicine) services.